IL161329A0 - Benzamide and heteroarylamide as p2x7 receptor antagonists - Google Patents

Benzamide and heteroarylamide as p2x7 receptor antagonists

Info

Publication number
IL161329A0
IL161329A0 IL16132902A IL16132902A IL161329A0 IL 161329 A0 IL161329 A0 IL 161329A0 IL 16132902 A IL16132902 A IL 16132902A IL 16132902 A IL16132902 A IL 16132902A IL 161329 A0 IL161329 A0 IL 161329A0
Authority
IL
Israel
Prior art keywords
heteroarylamide
benzamide
receptor antagonists
antagonists
receptor
Prior art date
Application number
IL16132902A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL161329A0 publication Critical patent/IL161329A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
IL16132902A 2001-11-12 2002-11-04 Benzamide and heteroarylamide as p2x7 receptor antagonists IL161329A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33678101P 2001-11-12 2001-11-12
PCT/IB2002/004613 WO2003042191A1 (fr) 2001-11-12 2002-11-04 Benzamide et heteroarylamide utilises comme antagonistes du recepteur p2x7

Publications (1)

Publication Number Publication Date
IL161329A0 true IL161329A0 (en) 2004-09-27

Family

ID=23317638

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16132902A IL161329A0 (en) 2001-11-12 2002-11-04 Benzamide and heteroarylamide as p2x7 receptor antagonists

Country Status (35)

Country Link
US (2) US7214677B2 (fr)
EP (1) EP1448535B1 (fr)
JP (1) JP4365218B2 (fr)
KR (1) KR20050043785A (fr)
CN (1) CN1585755A (fr)
AP (1) AP2004003028A0 (fr)
AR (1) AR038365A1 (fr)
AT (1) ATE502020T1 (fr)
BR (1) BR0214044A (fr)
CA (1) CA2466724C (fr)
CY (1) CY1111405T1 (fr)
DE (1) DE60239485D1 (fr)
DK (1) DK1448535T3 (fr)
EA (1) EA200400488A1 (fr)
EC (1) ECSP045097A (fr)
ES (1) ES2358988T3 (fr)
GT (1) GT200200224A (fr)
HN (1) HN2002000319A (fr)
HU (1) HUP0401936A3 (fr)
IL (1) IL161329A0 (fr)
IS (1) IS7216A (fr)
MA (1) MA27144A1 (fr)
MX (1) MXPA04004465A (fr)
NO (1) NO20041922L (fr)
OA (1) OA12718A (fr)
PA (1) PA8557501A1 (fr)
PE (1) PE20030537A1 (fr)
PL (1) PL370762A1 (fr)
PT (1) PT1448535E (fr)
PY (1) PY0227300A (fr)
SV (1) SV2004001393A (fr)
TN (1) TNSN04083A1 (fr)
UY (1) UY27535A1 (fr)
WO (1) WO2003042191A1 (fr)
ZA (1) ZA200402754B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2004058731A1 (fr) * 2002-12-31 2004-07-15 Pfizer Products Inc. Inhibiteurs benzamidiques du recepteur p2x7
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004092384A2 (fr) * 2003-04-17 2004-10-28 Affectis Pharmaceuticals Ag Moyens et methodes pour le diagnostic et le traitement de troubles affectifs
ES2281801T3 (es) * 2003-05-12 2007-10-01 Pfizer Products Inc. Inhibidores benzamida del receptor p2x7.
EP1837330B1 (fr) * 2003-05-12 2012-10-24 Pfizer Products Inc. Inhibiteurs benzamidiques du recepteur P2X7
EP1633401A1 (fr) * 2003-05-29 2006-03-15 AstraZeneca AB Composition pharmaceutique comprenant un antagoniste des recepteurs p2x7 et un facteur de necrose tumorale alpha
EP1644041A1 (fr) * 2003-05-29 2006-04-12 AstraZeneca AB Combinaison pharmaceutique comprenant un antagoniste du p2x7 et de la sulfasalazine
WO2004105796A1 (fr) * 2003-05-29 2004-12-09 Astrazeneca Ab Nouvelle combinaison
GB0312321D0 (en) * 2003-05-29 2003-07-02 Astrazeneca Ab New combination
EP1647151B1 (fr) * 2003-07-11 2014-06-04 Thomson Licensing Structure de microcellules de recouvrement pour reseau de systeme universel de telecommunication mobile
WO2005019182A1 (fr) * 2003-08-20 2005-03-03 Bayer Healthcare Ag Derives de pyrazolylmethylbenzamide utilises comme antagonistes du recepteur p2xt
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
ZA200603515B (en) * 2003-10-08 2007-11-28 Vertex Pharma Modulators of ATP-binding cassette transporters
ITMI20040255A1 (it) * 2004-02-17 2004-05-17 Univ Degli Studi Milano Sostanze ad attivita' antiangiogenica
JP2008504362A (ja) * 2004-06-29 2008-02-14 ファイザー・プロダクツ・インク Ｐ２ｘ７阻害活性をもつ５−［４−（２−ヒドロキシ−エチル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−［１，２，４］トリアジン−２−イル］−ベンズアミド誘導体を、トリアジンの４−位において置換されていない誘導体とオキシランをルイス酸の存在下で反応させることにより製造する方法
BRPI0512781A (pt) * 2004-06-29 2008-04-08 Pfizer Prod Inc método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila
CA2572119A1 (fr) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Therapies combinatoires dans lesquelles sont utilises des inhibiteurs de benzamide du recepteur p2x<sb>7</sb>
WO2006083214A1 (fr) * 2005-02-02 2006-08-10 Astrazeneca Ab Composition pharmaceutique comprenant un antagoniste du recepteur p2x7 et un inhibiteur de hmg-coa reductase
JPWO2006104172A1 (ja) * 2005-03-29 2008-09-11 興和株式会社 関節リウマチの予防及び／又は治療薬
WO2007008155A1 (fr) * 2005-07-11 2007-01-18 Astrazeneca Ab Nouvelle combinaison 1
WO2007008157A1 (fr) * 2005-07-11 2007-01-18 Astrazeneca Ab Nouvelle combinaison 2
EP2774925B1 (fr) 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Modulateurs hétérocycliques de transporteurs à cassette liant l'ATP
US20070117497A1 (en) * 2005-11-22 2007-05-24 Cabot Microelectronics Corporation Friction reducing aid for CMP
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
ES2604542T3 (es) * 2006-06-29 2017-03-07 F. Hoffmann-La Roche Ag Arilamidas con sustitución tetrazol
DE102006049618A1 (de) * 2006-10-20 2008-05-08 Tschesche, Harald, Prof. Dr. Triazine und Ihre Verwendung als Metalloproteinase-Inhibitoren
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008141119A2 (fr) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulateurs de cftr
CN103664637B (zh) 2007-06-29 2016-02-03 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
AU2008275891B2 (en) 2007-07-19 2013-10-10 H.Lundbeck A/S 5-membered heterocyclic amides and related compounds
TW200922548A (en) 2007-10-05 2009-06-01 Acucela Inc Alkoxy compounds for disease treatment
JP2011500767A (ja) 2007-10-26 2011-01-06 グラクソ グループ リミテッド Ｐ２ｘ７モジュレータとしての４−ベンゾイル−１−置換ピペラジン−２−オン誘導体
CL2008003120A1 (es) 2007-11-01 2009-10-09 Acucela Inc Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras.
PL2231606T3 (pl) 2007-12-07 2013-07-31 Vertex Pharma Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
HUE031913T2 (en) 2007-12-07 2017-08-28 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
GB2463151A (en) * 2008-09-05 2010-03-10 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
WO2010048332A2 (fr) * 2008-10-22 2010-04-29 Acucela, Inc. Composés de traitement de maladies et troubles ophtalmiques
ES2380908T3 (es) 2009-04-14 2012-05-21 Affectis Pharmaceuticals Ag Antagonistas de p2x7r novedosos y su uso
EP2448569B1 (fr) 2009-07-02 2021-10-27 Acucela, Inc. Pharmacologie de modulateurs du cycle visuel
EP2322149A1 (fr) 2009-11-03 2011-05-18 Universidad del Pais Vasco Procédés et compositions de traitement de l'ischémie
KR20120099155A (ko) 2010-01-07 2012-09-06 셀렉사겐 세라퓨틱스 인크. 헤지호그 저해제
WO2011085261A1 (fr) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Inhibiteurs de hedgehog
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
JP2013526496A (ja) 2010-05-14 2013-06-24 アフェクティス ファーマシューティカルズ アーゲー Ｐ２ｘ７ｒ拮抗剤の新規調製方法
WO2012110190A1 (fr) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Nouveaux antagonistes p2x7r et leur utilisation
WO2012114268A1 (fr) 2011-02-22 2012-08-30 Actelion Pharmaceuticals Ltd Dérivés de benzamide en tant qu'antagonistes du récepteur p2x7
CA2833806A1 (fr) * 2011-04-28 2012-11-01 Claire Mitchell Methode de traitement d'une degenerescence maculaire par la modulation des recepteurs p2y12 ou p2x7
WO2012163456A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2012163792A1 (fr) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
KR101995088B1 (ko) 2011-07-22 2019-07-02 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
NZ628910A (en) 2012-01-20 2016-02-26 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
MX355183B (es) 2012-01-25 2018-04-09 Vertex Pharma Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
TWI598325B (zh) 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 苯甲醯胺類
TW201427947A (zh) 2012-10-12 2014-07-16 Lundbeck & Co As H 環狀胺
PL2931717T3 (pl) 2012-12-12 2017-05-31 Actelion Pharmaceuticals Ltd. Pochodne indolokarboksyamidu jako antagoniści receptora p2x7
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
WO2014115078A1 (fr) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Dérivés d'amides hétérocycliques utilisés comme antagonistes du récepteur p2x7
KR102222220B1 (ko) 2013-01-22 2021-03-03 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
EP3019481B1 (fr) 2013-07-08 2019-03-06 Bayer CropScience Aktiengesellschaft Dérivés d'arylsulfure et d'arylsulfoxyde hexagonaux liés c-n comme moyens de lutte contre les parasites
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
US9988373B2 (en) 2013-12-26 2018-06-05 Shionogi & Co., Ltd. Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same
KR102576006B1 (ko) 2014-11-18 2023-09-06 버텍스 파마슈티칼스 인코포레이티드 고처리량 시험 고성능 액체 크로마토그래피의 수행 방법
EP3287443B1 (fr) 2015-04-24 2021-10-27 Shionogi & Co., Ltd Dérivé hétérocyclique à 6 chainons et composition pharmaceutique comprenant celui-ci
WO2018074390A1 (fr) 2016-10-17 2018-04-26 塩野義製薬株式会社 Dérivé hétérocyclique azoté bicyclique et composition pharmaceutique le comprenant
CN106674098B (zh) * 2016-12-23 2019-07-02 中国医科大学 N-(3-氰基-4-烷氧基苯基)吡啶甲酰胺类化合物及其用途
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
CN114315811B (zh) * 2021-11-19 2024-04-30 江苏恒盛药业有限公司 一种三氮唑类似物化合物及其制备方法和应用
WO2026041663A1 (fr) 2024-08-22 2026-02-26 Breye Therapeutics Aps Antagonistes du récepteur p2x7

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US71509A (en) * 1867-11-26 mcclellan
US142194A (en) * 1873-08-26 William w
US74576A (en) * 1868-02-18 Adam myers
US158883A (en) * 1875-01-19 Improvement in wax-thread sewing-machines
US128498A (en) * 1872-07-02 Improvement in tile-molds
US123378A (en) * 1872-02-06 Improvement in time-locks
US146200A (en) * 1874-01-06 Improvement in wind-wheels
US144213A (en) * 1873-11-04 Improvement in faucets
US71529A (en) * 1867-11-26 John e
US144170A (en) * 1873-10-28 Improvement in scarf-clasps
US77018A (en) * 1868-04-21 Improvement in dove-tail mabkers
AU542544B2 (en) * 1980-03-12 1985-02-28 Nippon Kayaku Kabushiki Kaisha Tetrahydrophthalimide derivatives
EP0077938A3 (fr) * 1981-10-23 1983-08-24 Mitsubishi Kasei Corporation Tétrahydrophtalimides N-(3-substituées aminophényl) et compositions herbicides les contenant
US4766233A (en) 1984-06-12 1988-08-23 Fmc Corporation Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof
EP0185731A4 (fr) 1984-06-12 1988-11-02 Fmc Corp 2-aryl-1,2,4-triazine-3,5(2h,4h)-diones herbicides et leurs analogues sulfures.
AU2328188A (en) * 1987-09-23 1989-04-18 Ciba-Geigy Ag Heterocyclic compounds
US5128351A (en) 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
US5077409A (en) 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
WO1992011242A1 (fr) 1990-12-17 1992-07-09 Shell Internationale Research Maatschappij B.V. Derives d'isoquinoline fongicides
JP3089621B2 (ja) * 1990-12-17 2000-09-18 日産化学工業株式会社 ウラシル誘導体
GB9110679D0 (en) * 1991-05-17 1991-07-10 Sandoz Ltd Improvements in or relating to organic compounds
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
DE4405614A1 (de) * 1994-02-22 1995-08-24 Bayer Ag Substituierte Triazolinone
US5686061A (en) 1994-04-11 1997-11-11 The Board Of Regents Of The University Of Texas System Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors
GB9412603D0 (en) * 1994-06-23 1994-08-10 Sandoz Ltd Organic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU1335897A (en) 1995-12-21 1997-07-17 Du Pont Merck Pharmaceutical Company, The Isoxazoline, isothiazoline and pyrazoline factor xa inhibitors
WO1997036862A1 (fr) 1996-03-29 1997-10-09 G.D. Searle & Co. DERIVES DE PHENYLENE META-SUBSTITUES, UTILISES COMME ANTAGONISTES OU INHIBITEURS DE L'INTEGRINE ALPHAvBETA¿3?
CN1246847A (zh) 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
DE19701287A1 (de) * 1997-01-16 1998-07-23 Wernicke & Co Gmbh Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben
WO1998042669A1 (fr) 1997-03-25 1998-10-01 Astra Pharmaceuticals Ltd. Nouveaux derives de pyridine et compositions pharmaceutiques les renfermant
WO1998043973A1 (fr) 1997-03-27 1998-10-08 Novartis Ag Produits intermediaires et procede pour preparer des derives de pyrimidine
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SE9704272D0 (sv) 1997-11-21 1997-11-21 Astra Pharma Prod Novel Compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11318492A (ja) 1998-03-09 1999-11-24 Aisin Seiki Co Ltd 蛍光発生性基質を含有する組成物
US6320078B1 (en) 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
NZ512339A (en) 1998-12-16 2003-03-28 Bayer Ag New biphenyl and biphenyl-analogous compounds as integrin antagonists
HUP0202214A3 (en) 1999-04-09 2002-12-28 Astrazeneca Ab Adamantane derivatives, preparation and use thereof
CA2374820A1 (fr) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibiteurs du facteur xa
SE9901875D0 (sv) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
EP1088821A1 (fr) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Derives des sulfamides pharmaceutiquement actifs
CA2387846A1 (fr) 1999-10-18 2001-04-26 University Of Connecticut Retro-anandamides, ligands des recepteurs des cannabinoides presentant une affinite et une stabilite elevees
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10005284A1 (de) 2000-02-07 2001-08-09 Bayer Ag Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (fr) 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
ES2281801T3 (es) 2003-05-12 2007-10-01 Pfizer Products Inc. Inhibidores benzamida del receptor p2x7.
JP2008504362A (ja) 2004-06-29 2008-02-14 ファイザー・プロダクツ・インク Ｐ２ｘ７阻害活性をもつ５−［４−（２−ヒドロキシ−エチル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−［１，２，４］トリアジン−２−イル］−ベンズアミド誘導体を、トリアジンの４−位において置換されていない誘導体とオキシランをルイス酸の存在下で反応させることにより製造する方法
CA2572119A1 (fr) 2004-06-29 2006-01-12 Warner-Lambert Company Llc Therapies combinatoires dans lesquelles sont utilises des inhibiteurs de benzamide du recepteur p2x<sb>7</sb>
BRPI0512781A (pt) 2004-06-29 2008-04-08 Pfizer Prod Inc método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila

Also Published As

Publication number Publication date
HUP0401936A3 (en) 2006-04-28
ES2358988T3 (es) 2011-05-17
PY0227300A (es) 2004-06-01
EP1448535A1 (fr) 2004-08-25
PL370762A1 (en) 2005-05-30
AP2004003028A0 (en) 2004-06-30
CN1585755A (zh) 2005-02-23
PT1448535E (pt) 2011-03-24
CY1111405T1 (el) 2015-08-05
ATE502020T1 (de) 2011-04-15
KR20050043785A (ko) 2005-05-11
DK1448535T3 (da) 2011-05-23
HUP0401936A2 (hu) 2005-01-28
IS7216A (is) 2004-04-07
PE20030537A1 (es) 2003-06-19
MA27144A1 (fr) 2005-01-03
WO2003042191A1 (fr) 2003-05-22
TNSN04083A1 (fr) 2006-06-01
US7214677B2 (en) 2007-05-08
JP4365218B2 (ja) 2009-11-18
OA12718A (en) 2006-06-27
ECSP045097A (es) 2004-06-28
CA2466724C (fr) 2009-10-27
CA2466724A1 (fr) 2003-05-22
DE60239485D1 (de) 2011-04-28
PA8557501A1 (es) 2003-06-30
NO20041922L (no) 2004-06-01
US7235549B2 (en) 2007-06-26
AR038365A1 (es) 2005-01-12
MXPA04004465A (es) 2004-08-11
EA200400488A1 (ru) 2004-10-28
EP1448535B1 (fr) 2011-03-16
US20060058302A1 (en) 2006-03-16
US20030186981A1 (en) 2003-10-02
GT200200224A (es) 2003-06-13
BR0214044A (pt) 2004-10-13
ZA200402754B (en) 2005-04-08
SV2004001393A (es) 2004-05-07
JP2005509653A (ja) 2005-04-14
HN2002000319A (es) 2003-12-20
UY27535A1 (es) 2003-06-30

Similar Documents

Publication Publication Date Title
PL370762A1 (en) Benzamide and heteroarylamide as p2x7 receptor antagonists
AU2002347022A1 (en) Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
HUP0302845A3 (en) 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
EP1541585A4 (fr) Antagoniste de cxcr4 et son utilisation
IL165841A0 (en) Mchir antagonists
IL162825A0 (en) Fluoro substituted cycloalkanoindoles and their use asprotaglandin d2 receptor antagonists
IL150632A0 (en) Corticotropin releasing factor antagonists
IL163824A0 (en) Substituted amides active at the cannabinoid-1 receptor
HUP0302382A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
EP1351933A4 (fr) Antagonistes des recepteurs de l&#39;il-8
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
EP1536813A4 (fr) Compositions et procedes comprenant des antagonistes des recepteurs actives de proteines
HUP0302003A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
AU2003225054A8 (en) Toll-like receptor 11 and toll-like receptor 12
AU2002364699A8 (en) Receptors and membrane-associated proteins
EP1359915A4 (fr) Antagonistes des recepteurs de l&#39;urotensine-ii
GB9820014D0 (en) Receptor antagonists and uses thereof
HUP0401535A3 (en) Somatostatin antagonists and their use
HUP0302614A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
AU2002359524A8 (en) P2x7 receptor antagonists
AU2003206014A8 (en) Neuropeptide receptor and uses thereof
AU2002309970A8 (en) Receptors and membrane-associated proteins
HUP0300470A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
IL161669A (en) Chemokine receptor antagonists and methods of use thereof